TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06590896: A Phase 2, Multicenter Open-Label Extension Study to Evaluate the Long-term Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures

Sponsor: Ono Pharmaceutical Co., Ltd. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$465,600

Rescue Site Savings

+$310,400

Unlock Full NCT06590896 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06590896 Rescue Dossier →